Study for Prevention of Cervical Cancer in Spain
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Evaluate the effectiveness of current Human Papillomavirus (HPV) vaccination and screening programs in reducing cervical cancer incidence in Spain..
- Who it may be relevant to
- Registry conditions: Cervical Cancer Screening, HPV Vaccination. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The REVIVE study aims to analyze the current status of Human Papillomavirus (HPV) vaccination programs and cervical cancer screening strategies in Spain. Its objective is to gain a comprehensive understanding of the effectiveness of these preventive measures, as well as to identify the main barriers to access and the existing inequalities in care. The study will also examine the impact of misinformation on population engagement and on the overall equity of the prevention system. Despite significant advances in both vaccination and screening efforts, cervical cancer remains a major public health concern in Spain. In 2024 alone, 2,259 new cases were diagnosed, that incidence has remained relatively stable in recent years, even decades. Mortality rates have also shown little change, with over 600 deaths annually, totaling nearly 10,000 in the last 15 years. To address this, the study plans to include approximately 200 patients diagnosed with cervical cancer in Spain between 2019 and 2024. It is a retrospective, observational, and non-interventional study. Data will be collected from existing medical records and supplemented with a specific questionnaire administered to the participating patients.
Interventions
- Biological Evaluate the effectiveness of current Human Papillomavirus (HPV) vaccination and screening programs in reducing cervical cancer incidence in Spain.
Data will be collected from existing medical records and supplemented with a specific questionnaire administered to the participating patients.
Primary outcome measures
- Prevalence of HPV vaccination and cervical cancer screening among patients diagnosed with cervical cancer in Spain [Time frame: 2019-2024]
Secondary outcome measures (3)
- Percentage of HPV vaccination and screening coverage by region and demographic factors [Time frame: 2019-2024]
- Association between misinformation and socioeconomic factors and the rate of HPV vaccination and screening [Time frame: 2019-2024]
- Reported frequency and nature of barriers to accessing to HPV vaccination and cervical cancer screening [Time frame: 2019-2014]
Eligibility criteria
Inclusion criteria
- Female patients diagnosed with squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix.
- Diagnosis established between 2019 and 2024.
Exclusion criteria
- Patients aged below 18 years at diagnosis.
- Diagnosis of other cervical cancer histologies (e.g., neuroendocrine tumors, sarcoma, lymphoma).
- Patents with significant cognitive impairment precluding informed consent for data utilization, where applicable.
- Patients with incomplete medical records relevant to the study variables.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07113379 · REVIVE